Randomized Trialhigh evidence
Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial.
Nature medicine·August 30, 2026·PMID 42742182
Why it mattersThe choice of background therapy may determine whether adding a TTR gene silencer provides incremental benefit in ATTR-CM. This analysis suggests that patients not already on a stabilizer are most likely to benefit from eplontersen, whereas those on stabilizers may not gain additional protection.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled